Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Altimmune, Inc.NASDAQ: ALT

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 financing cash flow of $78.47M rose 130.0% year over year, behind the +466.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at +53.9% a year.

Context

  • Financing cash flow amounted to 504492.7% of revenue in FY2025, up 454272.7 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +130.0% toward the trailing-twelve-month pace of +466.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$78.47M-3.3% QoQ
Last fiscal yearDec 2025
$206.84M+1959.4% YoY
LTMMar 2026
$251.49M+466.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+130.0%——
1 year+1959.4%——
3-year CAGR+53.9%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
206.84M USD
Year-over-year change
+1959.4%
4-year CAGR
+33.5%

Financing Cash Flow vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +466.1% is the 4th highest of 9, against a peer median of +357.4%.
  • Financing cash flow amounts to 698594.4% of revenue for ALT, versus a peer median of 243.2%.
ALT Competitors
Financing Cash Flow for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GPCRStructure Therapeutics Inc.LTM Jun 2026$759.79M USD+64071.1%+197.3%—
ALTAltimmune, Inc.LTM Mar 2026$251.49M USD+466.1%+53.9%698594.4%
IVAInventiva S.A.FY2025€232M EUR+59.4%+84.0%5175.1%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$172.89M USD+451.1%+557.7%243.2%
VIRVir Biotechnology, Inc.LTM Mar 2026$165.71M USD+3328.0%-52.2%253.0%
BMEABiomea Fusion, Inc.LTM Mar 2026$64.53M USD+1243.2%+279.8%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$42.1M USD+263.6%—60.8%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$14.88M USD+96.2%——
ABUSArbutus Biopharma CorporationLTM Mar 2026$14.56M USD-52.0%-43.6%7.6%
Peer median (excluding ALT) —+357.4%+140.6%243.2%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Depreciation & Amortization551K493K477K238K112K
Deferred Income Tax0000(681K)
Stock-Based Compensation5.52M8.1M10.64M14.39M16.08M
Change in Working Capital(251K)14.11M(8.27M)4.48M6.75M
Accounts Receivables6.53M3.3M(2.31M)1.74M2.06M
Inventory00000
Accounts Payables1.42M2.77M(2.73M)(1.86M)2.51M
Other Working Capital(8.21M)8.04M(3.23M)4.6M2.19M
Other Non-Cash Items13.03M(578K)9.79M(3.9M)(1.7M)
Operating Cash Flow(78.24M)(62.59M)(75.81M)(79.85M)(67.54M)
Capital Expenditures(12.31M)(126K)(47K)0(11K)
Acquisitions (Net)00000
Purchases of Investments(7.59M)(73.27M)(88.63M)(115.73M)(285.45M)
Sales of Investments107.43M0102.41M87.35M152.99M
Other Investing Activities(195K)0000
Investing Cash Flow87.52M(73.4M)13.73M(28.39M)(132.47M)
Debt Repayment000033.92M
Common Stock Issued65.04M56.35M86.6M9.99M173.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities58K434K(496K)50K(709K)
Financing Cash Flow65.1M56.78M86.11M10.04M206.84M
Effect of Forex Changes00000
Net Change in Cash74.38M(79.2M)24.03M(98.19M)6.83M
Free Cash Flow(90.55M)(62.71M)(75.86M)(79.85M)(67.55M)

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.